Patrick Urban

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

16h-index2.2kcitations67works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(13), HER2/EGFR in Cancer Research(10), Advanced Breast Cancer Therapies(10), Lung Cancer Treatments and Mutations(8), PI3K/AKT/mTOR signaling in cancer(8)

Publications67 total

Ianalumab plus Eltrombopag in Immune Thrombocytopenia
New England Journal of Medicine·2025
Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
Blood·2025Open Access
Pre-treatment immune profiling by flow cytometry and single-cell transcriptomics identifies distinct features in B and T cells in rituximab responders and non-responders
Blood·2025
Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy
Blood·2025
POSTER: MDS-882 A Phase 2 Study of Ianalumab in Patients With Primary Immune Thrombocytopenia Previously Treated With at Least Two Lines of Therapy (VAYHIT3)
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-882: A Phase 2 Study of Ianalumab in Patients With Primary Immune Thrombocytopenia Previously Treated With at Least Two Lines of Therapy (VAYHIT3)
Clinical Lymphoma Myeloma & Leukemia·2025
VAYHIT3: Phase 2 Study of Ianalumab in Previously Treated Patients With Primary Immune Thrombocytopenia
Kocaeli Üniversitesi - AVESİS·2025
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
Blood Advances·2025· 3 citedOpen Access
A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
Blood·2024· 1 citedOpen Access
A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)
Blood·2023Open Access
Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)
Blood·2023· 6 cited
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
Lung Cancer·2021· 17 citedOpen Access
Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients
Cancer Chemotherapy and Pharmacology·2019· 7 cited
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Breast Cancer Research and Treatment·2017· 63 citedOpen Access
P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis
Journal of Thoracic Oncology·2017
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
European Journal of Cancer·2017· 100 citedOpen Access
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology·2017· 574 citedOpen Access
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology·2017· 532 citedOpen Access
P3.02a-015 Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis
Journal of Thoracic Oncology·2017Open Access
444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ)
Annals of Oncology·2016· 1 cited
page 1 of 4Next →

Frequent Co-authors

Emmanuelle di Tomaso(10), Cristian Massacesi(9), Mario Campone(8), Vincent Vuaroqueaux(8), Urs Eppenberger(8), Serenella Eppenberger‐Castori(8), Ina Wunn(8), Constantin Klein(8), Martin Labuhn(7), Alice T. Shaw(5), Enriqueta Felip(5), Edward Wight(5), Hiroji Iwata(4), Javier Cortés(4), Michelino De Laurentiis(4), W. Jonat(4), Barbara Pistilli(4), Nichola Cooper(4), Lucio Crinò(3), Cesare Gridelli(3)